160 related articles for article (PubMed ID: 20128139)
1. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.
Mastaglia FL
Acta Myol; 2009 Oct; 28(2):66-71. PubMed ID: 20128139
[TBL] [Abstract][Full Text] [Related]
2. Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3.
Price P; Santoso L; Mastaglia F; Garlepp M; Kok CC; Allcock R; Laing N
Tissue Antigens; 2004 Nov; 64(5):575-80. PubMed ID: 15496200
[TBL] [Abstract][Full Text] [Related]
3. The association of sporadic inclusion body myositis and Sjögren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype.
Rojana-udomsart A; Needham M; Luo YB; Fabian V; Walters S; Zilko PJ; Mastaglia FL
Clin Neurol Neurosurg; 2011 Sep; 113(7):559-63. PubMed ID: 21507567
[TBL] [Abstract][Full Text] [Related]
4. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex.
Scott AP; Laing NG; Mastaglia F; Needham M; Walter MC; Dalakas MC; Allcock RJ
J Neuroimmunol; 2011 Jun; 235(1-2):77-83. PubMed ID: 21543121
[TBL] [Abstract][Full Text] [Related]
5. Familial inclusion body myositis in a mother and son with different ancestral MHC haplotypes.
Mastaglia F; Price P; Walters S; Fabian V; Miller J; Zilko P
Neuromuscul Disord; 2006 Nov; 16(11):754-8. PubMed ID: 16934978
[TBL] [Abstract][Full Text] [Related]
6. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases.
Needham M; James I; Corbett A; Day T; Christiansen F; Phillips B; Mastaglia FL
J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1056-60. PubMed ID: 18258695
[TBL] [Abstract][Full Text] [Related]
7. Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1.
Scott AP; Allcock RJ; Mastaglia F; Nishino I; Nonaka I; Laing N
Neuromuscul Disord; 2006 May; 16(5):311-5. PubMed ID: 16564169
[TBL] [Abstract][Full Text] [Related]
8. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype.
Mastaglia FL; Needham M; Scott A; James I; Zilko P; Day T; Kiers L; Corbett A; Witt CS; Allcock R; Laing N; Garlepp M; Christiansen FT
Neuromuscul Disord; 2009 Nov; 19(11):763-5. PubMed ID: 19720533
[TBL] [Abstract][Full Text] [Related]
9. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex.
Kok CC; Croager EJ; Witt CS; Kiers L; Mastaglia FL; Abraham LJ; Garlepp MJ
Immunogenetics; 1999 Jun; 49(6):508-16. PubMed ID: 10380695
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis.
Needham M; Corbett A; Day T; Christiansen F; Fabian V; Mastaglia FL
J Clin Neurosci; 2008 Dec; 15(12):1350-3. PubMed ID: 18815046
[TBL] [Abstract][Full Text] [Related]
11. Genetics of inclusion-body myositis.
Needham M; Mastaglia FL; Garlepp MJ
Muscle Nerve; 2007 May; 35(5):549-61. PubMed ID: 17366591
[TBL] [Abstract][Full Text] [Related]
12. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families.
Sivakumar K; Semino-Mora C; Dalakas MC
Brain; 1997 Apr; 120 ( Pt 4)():653-61. PubMed ID: 9153127
[TBL] [Abstract][Full Text] [Related]
13. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis.
Badrising UA; Schreuder GM; Giphart MJ; Geleijns K; Verschuuren JJ; Wintzen AR; Maat-Schieman ML; van Doorn P; van Engelen BG; Faber CG; Hoogendijk JE; de Jager AE; Koehler PJ; de Visser M; van Duinen SG;
Neurology; 2004 Dec; 63(12):2396-8. PubMed ID: 15623710
[TBL] [Abstract][Full Text] [Related]
14. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.
Gang Q; Bettencourt C; Machado PM; Fox Z; Brady S; Healy E; Parton M; Holton JL; Hilton-Jones D; Shieh PB; Zanoteli E; De Paepe B; De Bleecker J; Shaibani A; Ripolone M; Violano R; Moggio M; Barohn RJ; Dimachkie MM; Mora M; Mantegazza R; Zanotti S; Hanna MG; Houlden H;
Neurobiol Aging; 2015 Apr; 36(4):1766.e1-1766.e3. PubMed ID: 25670332
[TBL] [Abstract][Full Text] [Related]
15. Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis.
Scott AP; Laing NG; Mastaglia F; Dalakas M; Needham M; Allcock RJ
J Neuroimmunol; 2012 Sep; 250(1-2):66-70. PubMed ID: 22732452
[TBL] [Abstract][Full Text] [Related]
16. [Pathomechanism and prevalence of sporadic inclusion body myositis (sIBM)].
Suzuki N; Tateyama M; Warita H; Izumi R; Nishino I; Aoki M
Rinsho Shinkeigaku; 2011 Nov; 51(11):964-6. PubMed ID: 22277440
[TBL] [Abstract][Full Text] [Related]
17. Genetic advances in sporadic inclusion body myositis.
Gang Q; Bettencourt C; Houlden H; Hanna MG; Machado PM
Curr Opin Rheumatol; 2015 Nov; 27(6):586-94. PubMed ID: 26335925
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein epsilon alleles in sporadic inclusion body myositis: a reappraisal.
Needham M; Hooper A; James I; van Bockxmeer F; Corbett A; Day T; Garlepp MJ; Mastaglia FL
Neuromuscul Disord; 2008 Feb; 18(2):150-2. PubMed ID: 18060780
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and classification of sporadic inclusion body myositis (sIBM).
Catalán M; Selva-O'Callaghan A; Grau JM
Autoimmun Rev; 2014; 13(4-5):363-6. PubMed ID: 24424185
[TBL] [Abstract][Full Text] [Related]
20. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.
Needham M; Mastaglia FL
Lancet Neurol; 2007 Jul; 6(7):620-31. PubMed ID: 17582362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
